Biotech Stocks and the SVB Collapse – Here’s What We Know

Mina Tadrus, MA, JD, founder and chief executive of Tadrus Capital, says these firms will need to find alternative sources of cash — all while competing against other companies in the same straits.”

“The increased competition for funding could lead to higher valuations and more stringent terms, making it harder for smaller startups to access capital,” Tadrus said to Investor’s Business Daily.

“The fewer investment opportunities could mean fewer exit opportunities (initial public offerings or acquisitions) and lower returns for investors in venture-backed businesses.”

Source: Investor’s Business Daily

Author: Allison Gatlin

Continue reading here: Biotech Stocks And The SVB Collapse — Here’s What We Know | Investor’s Business Daily (


More Posts

Send Us A Message